Scarica l'app Stockscreener
17.40
3.12%
-0.56
Dopo l'orario di chiusura:
17.60
0.20
+1.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Has Sarepta Therapeutics (SRPT) Fallen Too Far After Its Sharp Multi‑Year Share Price Slide? - simplywall.st
Sarepta Therapeutics to announce fourth quarter and full-year 2025 financial results - marketscreener.com
Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Sarepta Therapeutics to Report Q4 and Full-Year 2025 Financial Results - Intellectia AI
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results - Business Wire
New York State Common Retirement Fund Has $703,000 Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
(SRPT) Risk Channels and Responsive Allocation - Stock Traders Daily
New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005 - huntingtonsdiseasenews.com
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Is Sarepta (SRPT) Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet? - simplywall.st
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up - BioSpace
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease - marketscreener.com
Sarepta (SRPT) Receives Green Light for Huntington's Disease Tri - GuruFocus
Sarepta receives approval to start SRP-1005 trial in New Zealand - TipRanks
Sarepta gets New Zealand approval for Huntington’s disease trial By Investing.com - Investing.com India
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease - TradingView
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease - Sarepta Therapeutics
SAREPTA gets approval to test Huntington's disease treatment in humans - StreetInsider
Jobs Data: Will Sarepta Therapeutics Inc outperform its industry peersJuly 2025 Rallies & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Assessing Sarepta Therapeutics (SRPT) Valuation After Positive Three Year EMBARK Data For Elevidys - Sahm
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion - MSN
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Closer Look at Its 5.38% Potential Upside - DirectorsTalk Interviews
AAV Gene Therapy Market is Thriving Worldwide | Novartis - openPR.com
Sarepta’s Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors - Sahm
Sarepta’s Elevidys Data Underscore Long Term Duchenne Therapy Durability - Yahoo Finance
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? - Yahoo Finance
Institutional Owners May Take Dramatic Actions as Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Recent 3.7% Drop Adds to One-year Losses - 富途牛牛
Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags - MarketBeat
(SRPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options - Nasdaq
How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - simplywall.st
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sell Signal: Can Sarepta Therapeutics Inc. be recession proofTrade Risk Summary & Weekly Top Performers Watchlists - mfd.ru
Regenxbio Falls Most Ever After Tumor Found in Trial Participant - Bloomberg.com
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Barclays - MarketBeat
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More - BioSpace
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD - The Globe and Mail
HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta (SRPT): Analyst Reiterates Sell Rating Due to Data Conce - GuruFocus
Sarepta eyes Elevidys sales comeback with positive Phase III data - Yahoo Finance
Sarepta Therapeutics (SRPT): Analyst Reiterates Sell Rating Toda - GuruFocus
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - BioSpace
Sarepta Therapeutics (SRPT) upgraded to buy: What does it mean for the stock? - MSN
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks - Sahm
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Short-Term Share Price Momentum - Yahoo Finance
Sarepta's Duchenne gene therapy slows disease progression, three-year data shows - MSN
Sarepta rises on three-year Elevidys data - MSN
Sarepta shifts to efficacy outlook with three-year Elevidys DMD data - BioWorld MedTech
Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. - Barron's
Market movers: Sarepta Therapeutics, US Rare Earth, SkyWater Technology, CoreWeave... - Proactive Investors
Positive new top-line Elevidys data lifts Sarepta - The Pharma Letter
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):